Ingenix

What Ingenix does

Ingenix (legal entity: Ingenix.ai Sp. z o.o.) is a Warsaw, Poland-based AI company founded in 2023 that builds a Biological Reasoning Engine for translational and clinical drug development decisions. The core technology is a Modality Fusion architecture that integrates best-in-class specialist AI models across biological scales (molecules to patients) and data modalities (clinical, omics, literature, imaging, pathways, molecular, mechanistic) by fusing at the representation level rather than chaining at the output level. The reasoning head is trained on proprietary scientific reasoning traces to produce stepwise mechanistic explanations with source-level provenance, and the underlying component models (Bolek, BioResearcher, OmicsLM, HADES, Fun-Omics) are published as arXiv preprints.

The engine is delivered exclusively through the Qualified Access Program (QAP), a high-touch, application-based managed-services engagement in which Ingenix operates the engine on partner data rather than licensing software. Partners apply with a specific translational or clinical question, and engagements are scoped with named project teams (project lead, lead scientist, executive sponsor) producing defined deliverables with reasoning traces. Target customers include large pharma (top 20), mid-cap pharma, biotech, and well-funded emerging biotech/ADC developers; pricing terms are negotiated during discovery and reflect early-partnership economics rather than standard commercial rates, with multi-year contracts and partners owning all IP from each engagement.

The company is led by founders Piotr Surma (CEO) and Adam Dancewicz (CTO), who previously built Applica (acquired by Snowflake in 2022). Commercial operations are led by CBO Guy Spigelman (formerly AWS Healthcare & Life Sciences Startups EMEA lead and AION Labs co-founder), with scientific guidance from Walid S. Kamoun (VP/Global Head R&D Oncology at Servier). Ingenix has raised approximately €22M across two disclosed equity rounds (€9M seed April 2025 led by Inovo.vc; €13M seed-extension June 2026 led by Sofinnova Partners) plus an EU grant of ~€4.3M, and holds ISO/IEC 27001, 27017, and 27018 certifications alongside AI Act compliance.

Name

Ingenix

Legal name

Ingenix.ai Sp. z o.o.

Website

https://ingenix.ai

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Ingenix builds a Biological Reasoning Engine on a proprietary Modality Fusion architecture that produces mechanistic, source-grounded hypotheses for translational and clinical drug development, delivering it exclusively to pharma and biotech partners through a high-touch, managed-services Qualified Access Program.

Ownership category

akta.pro rank

Product category

AI-driven drug discovery and translational medicine software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151)

SIC

Services-Computer Integrated Systems Design (7373), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

Keywords

• AI drug discovery
• Biological reasoning engine
• Translational medicine AI
• Clinical trial prediction
• Modality fusion models

Headquarters

HQ city

Warsaw

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Project-based Consulting Engagements: Fixed-term engagements scoped with defined milestones and deliverables. Partners receive outputs with reasoning traces. Terms negotiated during discovery and designed to reflect early partnership status through the Qualified Access Program.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Ingenix develops the Biological Reasoning Engine, an AI system built on a novel Modality Fusion architecture that integrates best-in-class specialist models across biological scales (molecules to patients) and modalities (clinical data, omics, literature, imaging, pathways) at the representation level. The engine is operated by Ingenix on behalf of pharma and biotech partners through the Qualified Access Program, producing decision-grade outputs with stepwise mechanistic traces and source-level provenance for translational and clinical R&D decisions.

Product overview

Ingenix is an AI and biology company that has developed the Biological Reasoning Engine as its core product, built on a novel Modality Fusion architecture that integrates best-in-class AI models across biological scales and modalities at the representation level. The company offers access to the engine exclusively through its Qualified Access Program, where Ingenix staff operate the engine on behalf of partner pharma and biotech teams. The Modality Fusion architecture is complemented by five proprietary benchmarks (Validated Biomarkers, GEO-OmicsQA, DILER, Drug Development Competence Benchmark, and one additional) and six research publications (Bolek, BioResearcher, OmicsLM, HADES, Simultaneous Learning from Bulk and Single-Cell, and Fun-Omics) that detail the component layers of the engine's architecture. The engine generates decision-grade outputs with stepwise mechanistic reasoning traces, enabling applications in IND positioning, ADC design, clinical positioning, and translational synthesis.

Differentiator

Problem solved

Functional benefit

Products and services

• Biological Reasoning Engine AI system based on Modality Fusion architecture that integrates best-in-class models across biological scales and modalities to reason from first principles about drug development. Produces decision-grade outputs with stepwise mechanistic traces and source-level provenance for translational and clinical R&D decisions.
• Qualified Access Program (QAP) Limited partner engagement program through which Ingenix operates the Biological Reasoning Engine on behalf of pharma and biotech teams. Includes a named project team (project lead, lead scientist, executive sponsor), defined scope with milestones, and outputs with reasoning traces. Partners own all project IP.
• Modality Fusion Architecture Architectural approach that integrates best-in-class AI models across biological modalities at the representation level (embeddings) rather than at the output level, enabling the reasoning head to reason directly across embeddings and highlight biological links emerging only when modalities are seen together.
• Validated Biomarkers Benchmark Expert-curated benchmark (n=30) of drug/method-of-action/indication pairs with biomarker positives and adjacent-biology negative controls, testing discrimination rather than recall. One of five proprietary benchmarks designed for R&D decision certification.
• GEO-OmicsQA Benchmark Benchmark (n=3,000) of free-text biological questions grounded in transcriptomics profiles plus natural-language context, testing multi-sample omics reasoning capability.
• DILER Benchmark Benchmark covering 935 hypotheses and 257 compounds, testing mechanistic narrative quality on Drug-Induced Liver Injury predictions with ranked causal pathways and severity labels.
• Drug Development Competence Benchmark Benchmark (n=109) stratified across ontology resolution, qualitative retrieval, and basic quantitative computation for drug development decision-making.
• Bolek Multimodal language model for molecular reasoning — the molecular reasoning layer that extracts and reasons over structural and physicochemical information directly from molecular embeddings.
• BioResearcher

Quantifiable outcome

• 15 candidate dual-payload ADC combinations produced in minutes (vs. years through conventional methods)
• +4 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature10 records

Partnerships

One partnership is on record.

• Servier (Walid S. Kamoun)minorOthersWalid S. Kamoun, VP and Global Head of R&D Oncology at Servier, serves as a Scientific Advisor to Ingenix. Advises on translational and clinical strategy in oncology. Previously at Takeda Pharmaceuticals.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Owkin: AI biotech applying multimodal machine learning to patient-level data to discover biomarkers, optimize clinical trial design, and support pharma R&D. Comparable to Ingenix in targeting translational and clinical decision support for pharma/biotech via AI, particularly in oncology.
• BenevolentAI: AI drug discovery company using knowledge graphs and ML to generate and validate drug development hypotheses for pharma partners. Directly comparable to Ingenix's reasoning-engine approach to translational hypothesis generation, particularly in immunology and oncology.
• InSilico Medicine: AI-driven drug discovery company with end-to-end platforms (e.g., PandaOmics) for target identification, generative chemistry, and clinical trial prediction. Ingenix's Lead Scientist Tomasz Jetka is a former Senior Scientist here. Highly comparable product overlap in target discovery and clinical trial outcome prediction.
• CytoReason: AI company building cell-cyber models from multi-omics and clinical data to support pharma R&D decision-making across indications. Closely comparable to Ingenix's omics reasoning layer (OmicsLM) and pharma-services delivery model for translational and clinical positioning.
• Atomwise: AI-driven small molecule design company partnering with pharma to accelerate hit identification and lead optimization. Comparable to Ingenix's molecular reasoning layer (Bolek) and its pharma partnership GTM via multi-year collaborations.
• Insitro: Machine-learning-driven drug discovery company building predictive models from large-scale, high-quality biological data to accelerate pharma R&D decisions. Closely comparable to Ingenix in selling AI-driven translational and clinical insights to pharma partners via partnership models.

Broad incumbents

• Recursion Pharmaceuticals: Publicly traded AI-driven drug discovery company combining high-throughput biology with foundation models to generate and validate therapeutic hypotheses. Highly comparable to Ingenix in using AI to generate translational and clinical hypotheses for pharma partners, but operates at much larger scale with wet-lab infrastructure and a wholly owned pipeline.

Others

• Snowflake: Cloud data platform that acquired Ingenix founders' previous company (Applica) in 2022. Not a direct competitor, but a meaningful ecosystem reference point — Snowflake provides the data infrastructure layer underpinning many life sciences AI workflows and represents a potential commercialization channel for Ingenix's outputs.

Emerging players

• Iambic Therapeutics (formerly Entos): AI-driven drug discovery company combining physics-based simulation with multimodal foundation models for clinical candidate design. Comparable to Ingenix in fusing multiple AI approaches (models, modalities) for translational and clinical-stage decisions.
• CrushBio (Crush Therapeutics / similar AI preclinical players): Reverie Labs (and adjacent preclinical AI biotechs) apply ML to early-stage drug discovery for pharma partners. Comparable to Ingenix as emerging AI-for-pharma players competing for similar enterprise partnership budgets in oncology and immunology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ingenix